株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

臓器機能アッセイ:医療機器のパイプライン評価

Organ Function Assays - Medical Devices Pipeline Assessment, 2019

発行 GlobalData 商品コード 666933
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
臓器機能アッセイ:医療機器のパイプライン評価 Organ Function Assays - Medical Devices Pipeline Assessment, 2019
出版日: 2019年11月01日 ページ情報: 英文 68 Pages
概要

当レポートでは、世界の臓器機能アッセイの市場における、主要なパイプライン製品とその治験の進行状況について調査すると共に、製品の機能・特性の比較分析 (治験の進行段階別) や、主要企業・組織のプロファイルおよび代表的製品、昨今の市場動静 (業績報告・資本取引動向など) といった情報を取りまとめてお届けいたします。

第1章 目次

第2章 イントロダクション

  • 臓器機能アッセイの概要

第3章 治験中の製品

  • パイプライン製品:治験段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:推定認証時期別
  • 現在進行中の治験

第4章 血液凝固分析装置:治験中のパイプライン製品、企業別

  • 臓器機能アッセイの企業:治験段階別のパイプライン製品
  • 臓器機能アッセイ:治験段階別のパイプライン製品

第5章 臓器機能アッセイ市場:企業・製品の概要

  • Boditech Med
  • CareDx Inc
  • China Medical Technologies Inc (Inactive)
  • Cornell University
  • Daxor Corp
  • EMD Millipore Corp
  • French National Institute of Health and Medical Research
  • HepQuant Llc
  • Humedics GmbH
  • Marx Biotechnology Ltd
  • Myriad Genetics Inc
  • Proteome Sciences Plc
  • Radboud University Nijmegen Medical Centre
  • Research & Diagnostic Antibodies LLC
  • Schnellgen, Inc

第6章 臓器機能アッセイ市場:昨今の動向 (全32件)

第7章 付録

図表

List of Tables

  • Table 1: Organ Function Assays - Pipeline Products by Stage of Development 7
  • Table 2: Organ Function Assays - Pipeline Products by Territory 8
  • Table 3: Organ Function Assays - Pipeline Products by Regulatory Path 9
  • Table 4: Organ Function A

List of Figures

  • Figure 1: Organ Function Assays - Pipeline Products by Stage of Development 7
  • Figure 2: Organ Function Assays - Pipeline Products by Territory 8
  • Figure 3: Organ Function Assays - Pipeline Products by Regulatory Path 9
  • Figure 4: Organ Funct
目次
Product Code: GDME0807EPD

GlobalData's Medical Devices sector report, "Organ Function Assays - Medical Devices Pipeline Assessment, 2019" provides an overview of Organ Function Assays currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Organ Function Assays pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Organ Function Assays under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Organ Function Assays and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Organ Function Assays under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

  • 1.1 List of Tables 4
  • 1.2 List of Figures 5

2 Introduction 6

  • 2.1 Organ Function Assays Overview 6

3 Products under Development 7

  • 3.1 Organ Function Assays - Pipeline Products by Stage of Development 7
  • 3.2 Organ Function Assays - Pipeline Products by Territory 8
  • 3.3 Organ Function Assays - Pipeline Products by Regulatory Path 9
  • 3.4 Organ Function Assays - Pipeline Products by Estimated Approval Date 10
  • 3.5 Organ Function Assays - Ongoing Clinical Trials 11

4 Organ Function Assays - Pipeline Products under Development by Companies 12

  • 4.1 Organ Function Assays Companies - Pipeline Products by Stage of Development 12
  • 4.2 Organ Function Assays - Pipeline Products by Stage of Development 13

5 Organ Function Assays Companies and Product Overview 14

  • 5.1 Boditech Med Inc Company Overview 14
    • 5.1.1 Boditech Med Inc Pipeline Products & Ongoing Clinical Trials Overview 14
  • 5.2 China Medical Technologies Inc (Inactive) Company Overview 15
    • 5.2.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 15
  • 5.3 Cornell University Company Overview 18
    • 5.3.1 Cornell University Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.4 Daxor Corp Company Overview 19
    • 5.4.1 Daxor Corp Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.5 DSX Therapeutics LLC Company Overview 20
    • 5.5.1 DSX Therapeutics LLC Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.6 French National Institute of Health and Medical Research Company Overview 21
    • 5.6.1 French National Institute of Health and Medical Research Pipeline Products & Ongoing Clinical Trials Overview 21
  • 5.7 HepQuant Llc Company Overview 22
    • 5.7.1 HepQuant Llc Pipeline Products & Ongoing Clinical Trials Overview 22
  • 5.8 Humedics GmbH Company Overview 28
    • 5.8.1 Humedics GmbH Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.9 Merck Millipore Corp Company Overview 29
    • 5.9.1 Merck Millipore Corp Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.10 Myriad Genetics Inc Company Overview 30
    • 5.10.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.11 Proteome Sciences Plc Company Overview 31
    • 5.11.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.12 Radboud University Medical Centre Company Overview 32
    • 5.12.1 Radboud University Medical Centre Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.13 Schnellgen, Inc Company Overview 33
    • 5.13.1 Schnellgen, Inc Pipeline Products & Ongoing Clinical Trials Overview 33

6 Organ Function Assays- Recent Developments 34

  • 6.1 Oct 01, 2019: Fortress Diagnostics announces £8m investment in new headquarters 34
  • 6.2 Sep 25, 2019: Myriad Genetics expands Board of Directors with two additional members 34
  • 6.3 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 35
  • 6.4 Aug 27, 2019: Chris Cournoyer joins CareDx Board of Directors 36
  • 6.5 Aug 13, 2019: Myriad Genetics reports fiscal fourth-quarter and full-year 2019 financial results 36
  • 6.6 Aug 01, 2019: CareDx reports second quarter 2019 results 38
  • 6.7 Jul 29, 2019: Siemens Healthineers continues to drive growth forward 39
  • 6.8 Jul 29, 2019: Changes in the Managing Board of Siemens Healthineers 41
  • 6.9 Jul 02, 2019: Grace Colon succeeds Amy Abernethy on the CareDx Board 41
  • 6.10 May 08, 2019: CareDx reports first quarter 2019 results 42
  • 6.11 May 07, 2019: Myriad Genetics reports fiscal third-quarter 2019 financial results 43
  • 6.12 May 02, 2019: Siemens Healthineers posts strong revenue and profit growth in the second quarter 44
  • 6.13 Apr 04, 2019: HepQuant's Disease Severity Index (DSI) demonstrates hepatic functional improvement in high percentage of NASH patients treated with obeticholic acid: Results from INTERCEPT 747-117 45
  • 6.14 Mar 06, 2019: CareDx reports fourth quarter and FY 2018 results 46
  • 6.15 Mar 04, 2019: Daxor Announces Rise in Kit Sales and Files Form N-CSR For 2018 48
  • 6.16 Feb 20, 2019: Keith Hoffman joins HepQuant as Clinical Lab Manager 48
  • 6.17 Feb 14, 2019: First patient enrolled in a pivotal trial of the HepQuant SHUNT Liver Diagnostic Test 49
  • 6.18 Feb 11, 2019: Siemens Healthineers to invest EUR 350 million in new Campus Forchheim 49
  • 6.19 Feb 05, 2019: Myriad Genetics reports fiscal second-quarter 2019 financial results 50
  • 6.20 Jan 23, 2019: Proteome Sciences: Year-end trading update 51
  • 6.21 Jan 07, 2019: CareDx Reports Preliminary Fourth Quarter and Full Year 2018 Financial Results 52
  • 6.22 Dec 31, 2018: Myriad Genetics announced its former CEO Peter Durkee Meldrum passed away 54
  • 6.23 Dec 17, 2018: CareDx Director Dr. Amy Abernethy Resigns Board Seat to Become Principal Deputy Commissioner of the FDA 55
  • 6.24 Dec 04, 2018: 10 Billion Lab Tests and Growing: Siemens Healthineers Mass. Manufacturing Expansion Largely Completed 55
  • 6.25 Dec 04, 2018: 10 billion lab tests and growing: Siemens Healthineers mass. Manufacturing expansion largely completed 56
  • 6.26 Nov 26, 2018: CareDx names Reginald Seeto, MB.BS, as president and chief business officer 57
  • 6.27 Nov 26, 2018: CareDx strengthens executive leadership team with the appointment of Reginald Seeto, MB.BS, as President and Chief Business Officer 57
  • 6.28 Nov 09, 2018: HepQuant receives IDE approval from U.S. FDA to initiate clinical trial of the SHUNT Liver Diagnostic Kit 58
  • 6.29 Nov 09, 2018: Mayo Clinic elects Kent Thielen, M.D., CEO of its Florida operations; Mayo's board of trustees also names two new members 58
  • 6.30 Nov 08, 2018: CareDx reports third quarter results 61
  • 6.31 Nov 06, 2018: Proteome Sciences: Trading update confirmation of preferred provider status 62
  • 6.32 Nov 05, 2018: Siemens Healthineers with strong finish in fourth quarter, full year targets for fiscal 2018 achieved 63

7 Appendix 65

  • 7.1 Methodology 65
  • 7.2 About GlobalData 68
  • 7.3 Contact Us 68
  • 7.4 Disclaimer 68
Back to Top